Search results for "Peritoneal neoplasms"

showing 10 items of 45 documents

Vena cava resection and bypass for recurrent cervical cancer

2021

A 42-year-old woman was diagnosed with a second para-aortic cervical cancer. The patient had undergone a radical hysterectomy with pelvic lymphadenectomy for FIGO stage IB1 squamous cervical cancer 3 years prior to current presentation. No adjuvant treatment was performed after the primary surgery

Adultmedicine.medical_specialtyVena cavacervical cancerretroperitoneal neoplasms Uterine Cervical NeoplasmUterine Cervical NeoplasmsRecurrent cervical cancerVena Cava InferiorResectionblood vesselgynecologic surgical proceduremedicineHumansStage (cooking)Radical HysterectomyCervical cancerbusiness.industryObstetrics and Gynecologyneoplasm recurrencemedicine.diseaseRetroperitoneal NeoplasmSurgeryOncologyFemaleNeoplasm Recurrence LocalPresentation (obstetrics)businessInternational Journal of Gynecologic Cancer
researchProduct

Peritoneal sarcomatosis 5 years after laparoscopic morcellation of uterine leiomyoma.

2017

In 2011, a 40-year-old woman underwent laparoscopic myomectomy with intraabdominal morcellation. Histology report showed leiomyoma without atypia, necrosis, or mitosis. In 2016, she complained of left lower quadrant pain; ultrasound examination revealed a left hypogastric mass in the site of trocar placement. Percutaneous biopsy results showed a low-grade endometrial stromal sarcoma (LGESS). At laparoscopy, we observed: multiple nodules on uterine serosa, left annex, vesical peritoneum (Figure 1), Douglas pouch (Supplementary Video1), previous left pelvic trocar site (Figure 2), greater omentum (Figure 3), and right/left diaphragm.

Adultmedicine.medical_specialtymedicine.medical_treatmentSarcoma Endometrial StromalMorcellationAnastomosisHysterectomyDouglas' Pouch03 medical and health sciences0302 clinical medicineUterine MyomectomyUterine NeoplasmmedicineHumansEndometrial Neoplasm030212 general & internal medicinePeritoneal Neoplasms030219 obstetrics & reproductive medicineUterine leiomyomaHysterectomyLeiomyomabusiness.industryAnastomosis SurgicalRectumObstetrics and GynecologySarcomatosismedicine.diseaseUterine myomectomySurgeryEndometrial NeoplasmsCell Transformation NeoplasticUterine NeoplasmsFemaleSarcomabusinessPeritoneal NeoplasmOmentumHumanAmerican journal of obstetrics and gynecology
researchProduct

The prognostic value of skeletal muscle index on clinical and survival outcomes after cytoreduction and HIPEC for peritoneal metastases from colorect…

2021

BACKGROUND Cytoreductive surgery (CRS) and hypertermic intraperitoneal chemotherapy (HIPEC) represent the most effective strategy to manage peritoneal metastases (PM). This systematic review and meta-analysis aimed to assess the impact of body composition on clinical outcomes in patients with PM. METHODS A systematic literature search was performed using Medline, Web of Science and EMBASE databases from inception to the 20st August 2020. Data were independently extracted by 3 authors. Newcastle-Ottawa Scale was used to assess quality and risk of bias of studies. Pooled analyses were performed using Mantel-Haenszel method to estimate overall effect size with mean differences or odd ratios (O…

Clinical nutritionSarcopeniamedicine.medical_specialtyColorectal cancerSettore MED/18 - CHIRURGIA GENERALEMEDLINESettore MED/49 - SCIENZE TECNICHE DIETETICHE APPLICATEHyperthermic Intraperitoneal ChemotherapyClinical nutritionBody compositionPostoperative ComplicationsClinical outcomesInternal medicineHumansMedicineProspective StudiesMuscle SkeletalPeritoneal NeoplasmsHIPECbusiness.industryPostoperative complicationSkeletal muscleCytoreduction Surgical ProceduresHyperthermia InducedGeneral MedicinePrognosismedicine.diseaseCombined Modality TherapyConfidence intervalSurvival RatePeritoneal metastasesmedicine.anatomical_structureOncologyMeta-analysisSarcopeniaSurgeryColorectal NeoplasmsbusinessEuropean Journal of Surgical Oncology
researchProduct

Cirugía de tumores retroperitoneales con afectación de vena cava: revisión de 18 casos

2018

Resumen Introducción El tumor retroperitoneal con extensión a la vena cava inferior (VCI) más frecuente es el carcinoma de células renales. Tiene una supervivencia a 5 años de hasta un 32% cuando se realiza nefrectomía radical y trombectomía. El tratamiento quirúrgico es complejo y puede necesitar el soporte de circulación extracorpórea y parada circulatoria e hipotermia. Métodos Estudio descriptivo, retrospectivo, mediante análisis de datos de pacientes intervenidos de tumores con invasión de la VCI entre 1992 y 2015. Se recogieron datos demográficos, tumorales, de técnica quirúrgica, intraoperatorios, posquirúrgicos y de mortalidad. Las variables cuantitativas se presentan como media±desv…

Gynecologymedicine.medical_specialtySupervivenciabusiness.industryTumores retroperitoneales Vena cava inferior Circulación extracorpórea Supervivencia Retroperitoneal neoplasms Inferior vena cava Extracorporeal circulation Survival analysislcsh:RCirculación extracorpórealcsh:Surgery030232 urology & nephrologyTumores retroperitonealeslcsh:Medicinelcsh:RD1-811030204 cardiovascular system & hematologyVena cava inferior03 medical and health sciences0302 clinical medicinemedicineSurgeryCardiology and Cardiovascular MedicinebusinessCirugía Cardiovascular
researchProduct

Primary omental tumor with ultrastructural features of cellular schwannoma and absence of S-100 antigen reactivity.

1989

Summary We report a primary well-delimited, large mesenchymal omental neoplasm which appeared in a 58 year old man without neurofibromatous traces. The histological and ultrastructural features were consistent with a Schwann cell origin. However, repeated immunohistochemical reactions failed to demonstrate protein S-100 antigen reactivity in the neoplasic cells, the latter only expressing vimentin. The differential diagnosis with hemangiopericytoma is proposed.

HemangiopericytomaMalePathologymedicine.medical_specialtybiologyMesenchymal stem cellS100 ProteinsSchwann cellVimentinCell BiologyMiddle Agedmedicine.diseaseImmunohistochemistryPathology and Forensic MedicinePeritoneal Neoplasmmedicine.anatomical_structureAntigenmedicinebiology.proteinImmunohistochemistryHumansDifferential diagnosisOmentumNeurilemmomaPeritoneal NeoplasmsPathology, research and practice
researchProduct

Using A Heating Cable Within The Abdomen To Make Hyperthermic Intraperitoneal Chemotherapy Easier: Feasibility And Safety Study In The Swine

2009

International audience; BACKGROUND: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a complex, expensive and time-consuming procedure. Despite its good results in the treatment of peritoneal carcinomatosis, these factors have precluded the wider use of this procedure around the world. We hypothesized that HIPEC could be performed by heating the liquid within the abdomen and thus avoiding the need for an external heating circuit and a pump. The aim of this study was to assess the feasibility and safety of an internal heating device for hyperthermic intraperitoneal chemotherapy in an experimental model. METHODS: Four large-white pigs underwent one-hour open intraperitoneal hyperthermia w…

Hyperthermiamedicine.medical_specialty[SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/SurgerySwinemedicine.medical_treatmentAntineoplastic Agents[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery030230 surgery03 medical and health sciences0302 clinical medicineMedicineAnimals[ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/SurgeryPeritoneal NeoplasmsChemotherapyThermal injurybusiness.industryExperimental modelCarcinomaPig modelGeneral MedicineEquipment DesignHyperthermia InducedNeoplasms Experimentalmedicine.disease3. Good healthSurgeryPeritoneal carcinomatosismedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisAbdomenFeasibility StudiesMedicineSurgeryHyperthermic intraperitoneal chemotherapyFemalebusinessInjections Intraperitoneal
researchProduct

Is the acidity of ascitic fluid a reliable index in making the presumptive diagnosis of spontaneous bacterial peritonitis?

1986

Ascitic fluid pH and arterial-ascitic fluid pH gradient were compared to ascitic fluid polymorphonuclear cell count in 84 patients with cirrhotic ascites and in 12 with malignant ascites to assess their role as diagnostic tests for spontaneous bacterial peritonitis and to clarify the relationship between ascitic fluid pH and lactate. Ascitic fluid pH was significantly lower (pH 7.30) in spontaneous bacterial peritonitis (n = 18) and probable spontaneous bacterial peritonitis (n = 12) than in sterileascites (pH 7.41; n = 54). Since blood pH levels were not different in the presence of infection, arterial-ascitic fluid pH gradient was significantly higher in spontaneous bacterial peritonitis …

Liver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisNeutrophilsBacterial PeritonitisBicarbonatePeritonitisPeritonitisGastroenterologypCO2chemistry.chemical_compoundLeukocyte CountSpontaneous bacterial peritonitisInternal medicineAscitesmedicineAscitic FluidHumansLactic AcidEscherichia coli InfectionsPeritoneal NeoplasmsAgedAscitic fluidHepatologybusiness.industryAscitesBacterial InfectionsHydrogen-Ion ConcentrationMiddle Agedmedicine.diseasechemistryLactatesFemalemedicine.symptombusinessHepatology (Baltimore, Md.)
researchProduct

Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

2013

Purpose Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation. Methods The study presented was a retrospective analysis of 50 gastrointestinal cancer patients treated with cetuximab in combination with either FOLFIRI or FOLFOX. One cohort of 15 patients received an in-house reactive skin protocol upon development of an exanthema. A second cohort of 15 patients received a skin prophylaxis starting with the first dose of cetuximab before clinical signs of toxicity. A third historic group o…

MaleCancer ResearchColorectal cancerAdministration TopicalAdministration OralCetuximabMinocyclineGastroenterologyPeritoneal NeoplasmPeritoneal NeoplasmsGastrointestinal NeoplasmsSkinHematologyintegumentary systemCetuximabTherapy reactiveMultimodal therapyVitamin K 1General MedicineMiddle AgedCombined Modality TherapyAnti-Bacterial AgentsSurvival RateTreatment OutcomeAppendiceal NeoplasmsOncologyColonic NeoplasmsAdenocarcinomaFemaleErratumQuinolizinesFluoroquinolonesmedicine.drugmedicine.medical_specialtyPrednisoloneEGFRDetergentsAntineoplastic AgentsAdenocarcinomaAntibodies Monoclonal HumanizedDisease-Free SurvivalMetronidazoleRashInternal medicineIntestinal NeoplasmsmedicineCombined Modality TherapyHumansSurvival rateAgedRetrospective StudiesOriginal PaperRectal Neoplasmsbusiness.industryRetrospective cohort studyAntibiotic ProphylaxisExanthemamedicine.diseaseDermatologydigestive system diseasesSurgerybusinessJournal of Cancer Research and Clinical Oncology
researchProduct

Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma - a Report of 2 Cases

2014

<b><i>Summary</i></b><b><i>Background: </i></b>Malignant ascites is a frequent complication in gastrointestinal malignancy and is unresponsive to systemic therapies. Therapeutic options are limited, and repeated paracentesis is associated with increased loss of fluids and proteins, and impaired quality of life. The bi-specific trifunctional antibody catumaxomab has been approved for the treatment of refractory ascites. It has been proposed that repeated application leads to formation of human anti-mouse antibodies with a decrease in effectiveness and potentially hypersensitivity reactions. <b><i>Case Report: </i></b>Her…

MaleCancer Researchmedicine.medical_specialtyCatumaxomabGastroenterologyStomach NeoplasmsInternal medicineAntibodies BispecificAscitesmedicineParacentesisCarcinomaHumansInfusions ParenteralPeritoneal Neoplasmsmedicine.diagnostic_testSignet ring cellbusiness.industryAscitesCancerHematologyMiddle Agedmedicine.diseaseTrifunctional antibodySurgeryOncologyRetreatmentFemalemedicine.symptomComplicationbusinessCarcinoma Signet Ring Cellmedicine.drugOncology Research and Treatment
researchProduct

Benign multicystic mesothelioma: A case report of recurrent disease in a young adult with familiarity for renal cell carcinoma

2019

Benign multi-cystic peritoneal mesothelioma (BMCM) is a very rare disease (about 150 cases observed). The aetiology is currently little-known, and the data collected, without having achieved conclusive re sults, identify two possible causes: neoplastic and reactive inflammatory. This case report refers to a recidivism of BCMC in a patient whose brother, few months before, underwent a left nephrectomy and right renal Radio Frequency Termo Ablation (RFTA) for bilateral papillary renal cell carcinoma. For the recurring trend, the onset in a male young patient without chronic inflammatory diseases evidence, the presence of a first degree relative with a rare carcinoma we supposed a neoplastic a…

MaleHumansMesothelioma CysticMiddle AgedNeoplasm Recurrence Localbenign multcystic mesotheliom renal cells kideny tumor familiarity oncologyCarcinoma Renal CellKidney NeoplasmsPeritoneal Neoplasms
researchProduct